CROHN'S COLITIS CURE

Exploring a novel score to assess the Patient Perceived Burden of Disease in Crohn's Disease and Ulcerative Colitis – Crohn's Colitis Cure (CCC) Data Insights Program

Su W, Gu B, Pipicella J, Wilson W, Kim A, Wark G, Giles E, Walker G, Forbes A, Su H, Dutt S, An Y, Lawrance I, Lynch K, Connor S, Andrews J

INTRODUCTION & AIM

- The prevalence and burden of inflammatory bowel disease (IBD) is rising globally.
- We propose a novel score to capture and quantify the patient-perceived burden of disease (PPBoD) in IBD, in a large real-world Australasian cohort.
- Possible relationships amongst PPBoD, demographics, disease and treatment factors were explored.

RESULTS - CONT:

- 73.6% resided in Australia (n=3171) and 26.4% in New Zealand (NZ) (n=1137). People living in NZ had higher PPBoD.
- Females, active smokers and those who had used corticosteroids in the last 14 months reported higher PPBoD.
- More people in Australia were on a Biologic or novel small molecule compared to NZ (55.6% vs 39.2%).

METHOD

- Crohn's Colitis Care (CCCare) de-identified Clinical Quality Registry (CQR) was interrogated in April 2024.
- Adults with CD and UC across 19 IBD centres with an outpatient encounter in the last 14 months were included.
- A novel PPBoD score was designated for CD and UC.

RESULTS:

PPBoD for UC

- 6,211 people with IBD were identified with a clinical assessment in the last 14 months.
- **57.2%,** (n=3551) had Crohn's Disease, **42.8%,** (n=2660)

- The utilisation of aminosalicylates did not differ across PPBoD categories.
- 1530 (24.6%) had a recent faecal calprotectin (FCP), people with no PPBoD were more likely to have biochemical remission (FCP < 100 mg/g).
- Data for endoscopic and radiological remission were available in **1391 (22.4%)** people; those with no PPBoD were more likely to be in remission.
- In people with **no PPBoD**, **1.2% had any days out of role** due to IBD. Those with higher PPBoD had more days out of role.

		None n = 2208	Mild n = 1343	Moderate n = 453	Significant n = 304	p-value
	Median Age, years (IQR)	40 (30-55)	43 (32-57)	42 (32-54)	39 (27-52)	
	Female, n (%)	998 (45.3)	663 (49.6)	268 (59.3)	185 (61.1)	< 0.001
	Median BMI, kg/m² (IQR)	25.5 (22.4-28.7)	26.1 (22.9-30.1)	25.6 (22.4-30.1)	25.2 (21.5-29.0)	
	Currently smoking, n (%)	137 (6.2)	109 (8.1)	31 (6.8)	38 (12.5)	< 0.001
	Advanced Therapy, n (%)	1214 (61.1)	775 (64.9)	265 (64.3)	179 (64.9)	< 0.001
	Steroids, n (%)	180 (8.2)	135 (10.1)	89 (19.6)	90 (29.6)	< 0.001
	Aminosalicylates, n (%)	829 (41.7)	468 (39.2)	153 (37.1)	113 (41.0)	0.26
	Immunomodulator, n (%)	797 (40.1)	469 (39.3)	140 (34.0)	133 (48.2)	< 0.01
	>1 days out of role due to IBD, n (%)*	24 (1.2)	68 (5.8)	50 (13.0)	69 (27.2)	< 0.001
	Faecal calprotectin, <100 mg/g, n (%)*	503 (66.3)	257 (57.1)	101 (55.5)	42 (30.2)	< 0.001
	Complete endoscopic and radiologic remission, n (%)*	333 (50.2)	203 (47.5)	74 (42.0)	30 (24.0)	< 0.001

had Ulcerative Colitis.

+

• **4,308** people with IBD had sufficient data to calculate PPBoD.


3 +

4

• 82.5% had either no or only mild PPBoD.

2

<pre>Nocturnal Bowel Frequency A measure of sleep disturbance 0 = None 1 = ≥ nocturnal bowel motion</pre>	Patient-rated general wellbeing A global consumer assessment 0 = Very well 1 = Slightly below par 2 = Poor 3 = Very Poor 4 = Terrible	Defecation Urgency A measure of confidence & anxiety around incontinence 0 = No urgency 1 = Hurry 2 = Immediately 3 = Incontinence	Stool Frequency A measure of the quanta of interruption to daily activities 0 = Less than usual or same as usual 1 = 1 to 2 movements more than normal 2 = 3 to 4 movements more than normal 3 = 5 or more movements more than normal	Abdominal Pain A symptom recognised to alarm consumers 0 = None 1 = Mild 2 = Moderate 3 = Severe	Rectal Bleeding A symptom recognised to alarm consumers 0 = No blood seen 1 = Streaks of blood with stool less than half the time 2 = Obvious blood with stool most of the time 3 = Blood alone passed
1	2	3	4	5	6



*Percentage of those with available data.

CONCLUSIONS

- Within this geographically dispersed cohort, the majority had either no or mild PPBoD.
- Smoking, steroid therapy and days out of role were all indicators associated with significant PPBoD.

6

• Further studies are required to validate this novel score to assess PPBoD in IBD.

For more information contact: info@c-c-cure.org, or visit www.c-c-cure.org